Remove 2023 Remove Clinical Research Remove Drug Development
article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. billion in 2023 to 1.2 billion in 2023 to 1.2 billion in 2035. billion in 2035. In today’s landscape, this requires tailored solutions and agility to address many new challenges.

article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How organoids can redefine pre-clinical research

Drug Target Review

They have the capacity to differentiate tissue-specific cell types that mimic the architecture and complexity of human organs, from brain, 3 to gut, 4 providing a platform for preclinical testing of new drugs, high-throughput drug screening and long-term toxicity screening. 2023 May;30(5):571–91. billion by 2030.

article thumbnail

How FSP Models Help Biotech Companies Augment Their Clinical Development Needs

PPD

Its ability to maneuver persistent drug development challenges, like patient recruitment, trial complexity and rising costs, will ultimately determine its success. FSP outsourcing is growing faster than FSO.

article thumbnail

3 Key Takeaways from Psychedelic Science 2023

Conversations in Drug Development Trends

With so many exciting developments in the last few years, it’s critical for the psychedelic community to come together to reflect on our progress, share the latest discoveries, and discuss the future of psychedelic research. Check out our full psychedelics offering, and meet the team responsible for planning your clinical trial.

Science 98
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). Silver Spring (MD): Food and Drug Administration (US); 2016-. Rodrigues AD. 113:9861002.

article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The global preclinical CRO market was estimated to be valued at US$5.7